Surgical Science Sweden AB (publ) (SUS) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Now I will hand over to the speakers, CEO Tom Englund and CFO Anna Ahlberg. Please go ahead. Welcome to this earnings call for Surgical Science for Q3 2025. My name is Tom Englund, CEO, and with me today I have our CFO Anna Ahlberg. Q3 was a clear step in the right direction for Surgical Science. Total sales of 264 million SEK was an all time high for the company. And this result was despite the negative impact on sales from currencies of five percentage points. The group grew by 14% compared to the same quarter last year and by 19% adjusted for currency effects. Adjusted EBIT amounted to 33 million SEK, and was negatively impacted by restructuring costs of 2 million. Adjusted for these costs, profitability was 13%. Since around six months back, we have initiated a set of activities to improve our profitability, primarily focused on our hardware and software simulator business, that is not the robotics or development business. And we're now happy to see that these activities are beginning to have an effect, and we expect further improvements in the quarters to come. Speaking about educational products, this business unit stabilized during the quarter from the weak revenue of the previous quarter. We saw a growth of 8% compared to the same quarter in 2024 and 26% compared to the previous quarter. We saw good demand and customer activity in several regions during the quarter, with Europe showing the strongest growth at 46%. The entire ultrasound simulation segment, which became a strategic focus area in connection with the acquisition of intelligent ultrasound, also developed positively with high customer demand in all markets except for the UK. In the UK, we continue to see problems and sluggishness in the allocation of funds from the National Health Service, NHS, whi...